LJPC up +8.31% percent Today $LJPC High is at 13.66 and the Low 12.30 with current volume of 191,018.
Recent News posted below.
La Jolla Pharma LJPC other info.
http://investorshangout.com/La-Jolla-Pharmace...JPC-63793/
LJPC La Jolla Pharma Recent Headline News
La Jolla Pharmaceutical (LJPC) in Focus: Stock Surges 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:44AM CST
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares surge over 10% on the day
ENDP: 69.16 (+0.20), LCI: 51.37 (+1.20), BCRX: 10.93 (+0.47), LJPC: 13.45 (+1.17)
La Jolla Pharmaceutical Co. (LJPC) Jumps: Stock Rises 10.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 8:32AM CDT
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares rise more than 10% on the day.
LJPC: 13.45 (+1.17), CEMP: 13.86 (+0.10), IG: 9.57 (+0.12), BIOD: 1.51 (-0.03)
5 Stocks Spiking on Unusual Volume
at The Street - Mon Oct 27, 6:00AM CDT
Keep these stocks trading on unusual volume on your trading radar.
SUSP: 46.00 (+0.69), LJPC: 13.45 (+1.17), IPCM: 38.75 (-0.35), EGBN: 34.92 (+0.11), CSL: 88.94 (+0.19)
La Jolla Pharmaceutical Company Announces Data Presentation at the American Society of Nephrology Kidney Week
Business Wire - Thu Oct 23, 3:01PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) ("the Company" or "La Jolla"
, a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that an abstract of the results for the Company's Phase 2 clinical trial of GCS-100 in chronic kidney disease (CKD) has been selected by the American Society of Nephrology's (ASN) Program Committee for poster presentation at the Kidney Week Annual Meeting. Kidney Week will be held November 11-16, 2014 in Philadelphia, Pennsylvania.
LJPC: 13.45 (+1.17)
La Jolla (LJPC) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 9:41AM CDT
La Jolla (LJPC) Shares March Higher, Can It Continue?
LJPC: 13.45 (+1.17)
La Jolla (LJPC) is Oversold: Can It Recover? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 10:43AM CDT
La Jolla (LJPC) is Oversold: Can It Recover?
LJPC: 13.45 (+1.17)
La Jolla Pharmaceutical Company to Provide Corporate Overview at the Rodman & Renshaw 16th Annual Global Investment Conference
Business Wire - Mon Sep 08, 7:01AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla" , a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Rodman & Renshaw 16th Annual Global Investment Conference taking place September 8-10 in New York City.
LJPC: 13.45 (+1.17)
La Jolla Pharmaceutical Company Announces First Patient Enrolled in Clinical Trial of LJPC-501 in Hepatorenal Syndrome
Business Wire - Mon Aug 25, 7:04AM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the first patient has been enrolled in the Phase 1/2 clinical trial of LJPC-501 for the treatment of type 1 and type 2 hepatorenal syndrome (HRS). HRS is a life-threatening form of progressive renal failure in patients with liver cirrhosis or fulminant liver failure.
LJPC: 13.45 (+1.17)
La Jolla Pharmaceutical Company Announces Second Quarter and Year-to-Date 2014 Financial Results
Business Wire - Thu Aug 14, 3:30PM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported second quarter and year-to-date 2014 financial results and highlighted recent corporate progress.
LJPC: 13.45 (+1.17)
La Jolla Pharmaceutical Company Receives Notice of Allowance for Additional Patent Claims Covering Modified Pectin for the Treatment of Chronic Inflammation
Business Wire - Thu Aug 14, 7:00AM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla" , a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the United States Patent and Trademark Office ("USPTO" has issued a notice of allowance for patent application number 14/254,510 covering methods of treating chronic inflammation by intravenous administration of aqueous modified pectin solutions with molecular weights greater than 25 kilodaltons.
LJPC: 13.45 (+1.17)
Is ViaSat (VSAT) Poised to Surprise Q1 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 11:50AM CDT
Satellite communications company ViaSat Inc. (VSAT), is set to release its first-quarter fiscal 2015 financial numbers after the closing bell on Aug 12, 2014.
CPG: 31.98 (-0.55), LJPC: 13.45 (+1.17), JCP: 7.28 (-0.54), VSAT: 63.00 (-2.39)
La Jolla Pharmaceutical Company to Provide Corporate Overview at the 2014 Wedbush Securities Life Sciences Conference
Business Wire - Mon Aug 11, 7:01AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla" , a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, will provide a corporate overview at the 2014 Wedbush Securities Life Sciences Conference taking place August 12-13 in New York City.
LJPC: 13.45 (+1.17)
Galectin Drug is a Fatty Liver Flop
at The Street - Tue Jul 29, 9:26AM CDT
Across just about every biomarker for efficacy Galectin thought to measure, GR-MD-02 showed no difference from placebo in a phase I study.
LJPC: 13.45 (+1.17), GALT: 4.90 (-0.38)
La Jolla Pharmaceutical Company Closes Offering of Common Stock
Business Wire - Mon Jul 28, 5:29PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla" , a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced the closing of its underwritten public offering of 5,395,000 shares of common stock at a public offering price of $10.50 per share, which includes the partial exercise of the underwriters' option to purchase up to an additional 720,000 shares of common stock. Gross offering proceeds are approximately $56.6 million, including proceeds from the partial exercise of the underwriters' option to purchase additional shares, before deducting customary underwriting discounts and commissions and offering expenses.
LJPC: 13.45 (+1.17)
4 Biotech Stocks Breaking Out on Big Volume
at The Street - Thu Jul 24, 8:25AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
ACRX: 6.00 (-0.04), OMED: 20.08 (-0.11), LJPC: 13.45 (+1.17), LGND: 54.42 (+0.48)
La Jolla Pharmaceutical Company Announces Pricing of Underwritten Offering of Common Stock
Business Wire - Wed Jul 23, 8:14AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla" , a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced the pricing of an underwritten offering of 4,800,000 shares of its common stock, offered at a price of $10.50 per share. La Jolla has granted the underwriters a 30-day option to purchase up to an additional 720,000 shares of common stock. The offering is expected to close on or about July 28, 2014, subject to customary closing conditions. Jefferies LLC is acting as sole book-runner for the offering. Chardan Capital Markets, LLC, H.C. Wainwright & Co., LLC, LifeSci Capital, LLC and Noble Financial Group, Inc. are acting as co-managers for the offering.
LJPC: 13.45 (+1.17)
La Jolla Pharmaceutical Company Announces Proposed Underwritten Offering of Common Stock
Business Wire - Tue Jul 22, 3:01PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla" , a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to its existing shelf registration statement. All of the shares in the proposed offering are to be sold by La Jolla.
LJPC: 13.45 (+1.17)
La Jolla Pharmaceutical Company Analyst Initiation of Coverage: Steer Clear of this Company with a History of Failure by BrokerBank Securities, Inc.
PR Newswire - Thu Jul 17, 3:30PM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) is a biopharmaceutical company focused on the development of therapeutic agents that inhibit the activity of galectins as a means of treating human diseases such as chronic organ failure and cancer. The company's main product candidates include GCS-100 for the treatment of chronic kidney disease (CKD), LJPC-501 that is designed to help restore kidney function in patients with hepatorenal syndrome (HRS), and LJPC-401 for the treatment of iron disorders. In addition, LJPC is also developing LJPC-1010, which is an oral derivative of GCS-100 for the treatment of non-alcoholic steatohepatitis (NASH). Further, LJPC is also engaged in pre-clinical testing for LJPC-201 for hepatic fibrosis and LJPC-101 for end-stage renal disease (ESRD).
LJPC: 13.45 (+1.17)
Will La Jolla (LJPC) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 7:48AM CDT
Will La Jolla (LJPC) Continue to Surge Higher?
LJPC: 13.45 (+1.17)
La Jolla Pharmaceutical Announces Positive Pre-Clinical Data for Oral Galectin-3 Inhibitor in Nonalcoholic Steatohepatitis (NASH)
Business Wire - Tue Jul 15, 7:01AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla" , a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced positive pre-clinical data for LJPC-1010 in non-alcoholic steatohepatitis (NASH). LJPC-1010 is a derivative of GCS-100, a carbohydrate inhibitor of galectin-3, which has shown activity in chronic kidney disease in a Phase 2 trial.
LJPC: 13.45 (+1.17)
Recent News posted below.
La Jolla Pharma LJPC other info.
http://investorshangout.com/La-Jolla-Pharmace...JPC-63793/
LJPC La Jolla Pharma Recent Headline News
La Jolla Pharmaceutical (LJPC) in Focus: Stock Surges 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:44AM CST
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares surge over 10% on the day
ENDP: 69.16 (+0.20), LCI: 51.37 (+1.20), BCRX: 10.93 (+0.47), LJPC: 13.45 (+1.17)
La Jolla Pharmaceutical Co. (LJPC) Jumps: Stock Rises 10.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 8:32AM CDT
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares rise more than 10% on the day.
LJPC: 13.45 (+1.17), CEMP: 13.86 (+0.10), IG: 9.57 (+0.12), BIOD: 1.51 (-0.03)
5 Stocks Spiking on Unusual Volume
at The Street - Mon Oct 27, 6:00AM CDT
Keep these stocks trading on unusual volume on your trading radar.
SUSP: 46.00 (+0.69), LJPC: 13.45 (+1.17), IPCM: 38.75 (-0.35), EGBN: 34.92 (+0.11), CSL: 88.94 (+0.19)
La Jolla Pharmaceutical Company Announces Data Presentation at the American Society of Nephrology Kidney Week
Business Wire - Thu Oct 23, 3:01PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) ("the Company" or "La Jolla"
, a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that an abstract of the results for the Company's Phase 2 clinical trial of GCS-100 in chronic kidney disease (CKD) has been selected by the American Society of Nephrology's (ASN) Program Committee for poster presentation at the Kidney Week Annual Meeting. Kidney Week will be held November 11-16, 2014 in Philadelphia, Pennsylvania. LJPC: 13.45 (+1.17)
La Jolla (LJPC) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 9:41AM CDT
La Jolla (LJPC) Shares March Higher, Can It Continue?
LJPC: 13.45 (+1.17)
La Jolla (LJPC) is Oversold: Can It Recover? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 10:43AM CDT
La Jolla (LJPC) is Oversold: Can It Recover?
LJPC: 13.45 (+1.17)
La Jolla Pharmaceutical Company to Provide Corporate Overview at the Rodman & Renshaw 16th Annual Global Investment Conference
Business Wire - Mon Sep 08, 7:01AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"
, a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Rodman & Renshaw 16th Annual Global Investment Conference taking place September 8-10 in New York City. LJPC: 13.45 (+1.17)
La Jolla Pharmaceutical Company Announces First Patient Enrolled in Clinical Trial of LJPC-501 in Hepatorenal Syndrome
Business Wire - Mon Aug 25, 7:04AM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the first patient has been enrolled in the Phase 1/2 clinical trial of LJPC-501 for the treatment of type 1 and type 2 hepatorenal syndrome (HRS). HRS is a life-threatening form of progressive renal failure in patients with liver cirrhosis or fulminant liver failure.
LJPC: 13.45 (+1.17)
La Jolla Pharmaceutical Company Announces Second Quarter and Year-to-Date 2014 Financial Results
Business Wire - Thu Aug 14, 3:30PM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported second quarter and year-to-date 2014 financial results and highlighted recent corporate progress.
LJPC: 13.45 (+1.17)
La Jolla Pharmaceutical Company Receives Notice of Allowance for Additional Patent Claims Covering Modified Pectin for the Treatment of Chronic Inflammation
Business Wire - Thu Aug 14, 7:00AM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla"
, a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the United States Patent and Trademark Office ("USPTO" has issued a notice of allowance for patent application number 14/254,510 covering methods of treating chronic inflammation by intravenous administration of aqueous modified pectin solutions with molecular weights greater than 25 kilodaltons. LJPC: 13.45 (+1.17)
Is ViaSat (VSAT) Poised to Surprise Q1 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 11:50AM CDT
Satellite communications company ViaSat Inc. (VSAT), is set to release its first-quarter fiscal 2015 financial numbers after the closing bell on Aug 12, 2014.
CPG: 31.98 (-0.55), LJPC: 13.45 (+1.17), JCP: 7.28 (-0.54), VSAT: 63.00 (-2.39)
La Jolla Pharmaceutical Company to Provide Corporate Overview at the 2014 Wedbush Securities Life Sciences Conference
Business Wire - Mon Aug 11, 7:01AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"
, a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, will provide a corporate overview at the 2014 Wedbush Securities Life Sciences Conference taking place August 12-13 in New York City. LJPC: 13.45 (+1.17)
Galectin Drug is a Fatty Liver Flop
at The Street - Tue Jul 29, 9:26AM CDT
Across just about every biomarker for efficacy Galectin thought to measure, GR-MD-02 showed no difference from placebo in a phase I study.
LJPC: 13.45 (+1.17), GALT: 4.90 (-0.38)
La Jolla Pharmaceutical Company Closes Offering of Common Stock
Business Wire - Mon Jul 28, 5:29PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"
, a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced the closing of its underwritten public offering of 5,395,000 shares of common stock at a public offering price of $10.50 per share, which includes the partial exercise of the underwriters' option to purchase up to an additional 720,000 shares of common stock. Gross offering proceeds are approximately $56.6 million, including proceeds from the partial exercise of the underwriters' option to purchase additional shares, before deducting customary underwriting discounts and commissions and offering expenses. LJPC: 13.45 (+1.17)
4 Biotech Stocks Breaking Out on Big Volume
at The Street - Thu Jul 24, 8:25AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
ACRX: 6.00 (-0.04), OMED: 20.08 (-0.11), LJPC: 13.45 (+1.17), LGND: 54.42 (+0.48)
La Jolla Pharmaceutical Company Announces Pricing of Underwritten Offering of Common Stock
Business Wire - Wed Jul 23, 8:14AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"
, a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced the pricing of an underwritten offering of 4,800,000 shares of its common stock, offered at a price of $10.50 per share. La Jolla has granted the underwriters a 30-day option to purchase up to an additional 720,000 shares of common stock. The offering is expected to close on or about July 28, 2014, subject to customary closing conditions. Jefferies LLC is acting as sole book-runner for the offering. Chardan Capital Markets, LLC, H.C. Wainwright & Co., LLC, LifeSci Capital, LLC and Noble Financial Group, Inc. are acting as co-managers for the offering. LJPC: 13.45 (+1.17)
La Jolla Pharmaceutical Company Announces Proposed Underwritten Offering of Common Stock
Business Wire - Tue Jul 22, 3:01PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"
, a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to its existing shelf registration statement. All of the shares in the proposed offering are to be sold by La Jolla. LJPC: 13.45 (+1.17)
La Jolla Pharmaceutical Company Analyst Initiation of Coverage: Steer Clear of this Company with a History of Failure by BrokerBank Securities, Inc.
PR Newswire - Thu Jul 17, 3:30PM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) is a biopharmaceutical company focused on the development of therapeutic agents that inhibit the activity of galectins as a means of treating human diseases such as chronic organ failure and cancer. The company's main product candidates include GCS-100 for the treatment of chronic kidney disease (CKD), LJPC-501 that is designed to help restore kidney function in patients with hepatorenal syndrome (HRS), and LJPC-401 for the treatment of iron disorders. In addition, LJPC is also developing LJPC-1010, which is an oral derivative of GCS-100 for the treatment of non-alcoholic steatohepatitis (NASH). Further, LJPC is also engaged in pre-clinical testing for LJPC-201 for hepatic fibrosis and LJPC-101 for end-stage renal disease (ESRD).
LJPC: 13.45 (+1.17)
Will La Jolla (LJPC) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 7:48AM CDT
Will La Jolla (LJPC) Continue to Surge Higher?
LJPC: 13.45 (+1.17)
La Jolla Pharmaceutical Announces Positive Pre-Clinical Data for Oral Galectin-3 Inhibitor in Nonalcoholic Steatohepatitis (NASH)
Business Wire - Tue Jul 15, 7:01AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"
, a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced positive pre-clinical data for LJPC-1010 in non-alcoholic steatohepatitis (NASH). LJPC-1010 is a derivative of GCS-100, a carbohydrate inhibitor of galectin-3, which has shown activity in chronic kidney disease in a Phase 2 trial. LJPC: 13.45 (+1.17)
